As of January 22, 2025, Celltrion (068270.KS) has a market cap of $27.10 billion USD. According to our data, Celltrion is ranked No.726 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $27.10 B |
-3.73%
|
Dec 30, 2024 | $28.15 B |
-1.89%
|
Dec 28, 2023 | $28.70 B |
25.88%
|
Dec 29, 2022 | $22.80 B |
-15.50%
|
Dec 30, 2021 | $26.98 B |
-43.53%
|
Dec 30, 2020 | $47.78 B |
102.31%
|
Dec 30, 2019 | $23.62 B |
-14.58%
|
Dec 28, 2018 | $27.65 B |
2.65%
|
Dec 28, 2017 | $26.94 B |
109.98%
|
Dec 29, 2016 | $12.83 B |
33.46%
|
Dec 30, 2015 | $9.61 B |
124.03%
|
Dec 30, 2014 | $4.29 B |
6.37%
|
Dec 30, 2013 | $4.03 B |
-24.33%
|
Dec 28, 2012 | $5.33 B |
24.09%
|
Dec 29, 2011 | $4.30 B |
8.69%
|
Dec 30, 2010 | $3.95 B |
123.90%
|
Dec 30, 2009 | $1.77 B |
51.52%
|
Dec 31, 2008 | $1.16 B |
226.73%
|
Dec 28, 2007 | $0.36 B |
-29.76%
|
Dec 28, 2006 | $0.51 B |
-30.68%
|
Dec 29, 2005 | $0.73 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Amgen
AMGN
|
$147.53 B |
0.002 M
|
USA
|
Biogen
BIIB
|
$20.80 B |
-0.001 M
|
USA
|
Gilead Sciences
GILD
|
$116.07 B |
0.004 M
|
USA
|
Regeneron Pharmaceuticals
REGN
|
$75.23 B |
1.245 B
|
USA
|
Novartis
NVS
|
$197.43 B |
0.007 M
|
Switzerland
|
Pfizer
PFE
|
$148.34 B |
-0.006 M
|
USA
|
Merck
MRK
|
$242.59 B |
0.007 M
|
USA
|
Bristol-Myers Squibb
BMY
|
$115.86 B |
0.003 M
|
USA
|
Sanofi
SNY
|
$128.55 B |
0.003 M
|
France
|
AbbVie
ABBV
|
$300.53 B |
0.002 M
|
USA
|
Eli Lilly
LLY
|
$676.92 B |
0.020 M
|
USA
|
Johnson & Johnson
JNJ
|
$347.78 B |
-0.005 M
|
USA
|
AstraZeneca
AZN
|
$211.43 B |
0.005 M
|
UK
|
GlaxoSmithKline
GSK
|
$68.38 B |
0.002 M
|
UK
|
Market Cap | = | 068270.KS Stock Price | * | 068270.KS Shares Outstanding |
= | $125.94 | * | 0.22 B | |
= | $27.10 B |